The website for professionals in Laboratory Medicine

Prevention and treatment of viral respiratory tract infections

Pneumagen, a clinical-stage biotechnology company developing Neumifil, a broad-spectrum antiviral intranasal drug, has reported positive topline data from a phase 1 study designed to evaluate safety and tolerability in healthy volunteers.

The phase 1, single-entre, two-part randomised, double-blind, placebo-controlled dose escalation study enrolled a total of 60 healthy volunteers who were evaluated for safety and tolerability of single and multiple doses of Neumifil.  Top line data from the trial show that Neumifil is well tolerated with no dose limiting toxicities and a safety profile that strongly supports further development. No serious adverse events were reported at any of the doses evaluated in the study.  

Neumifil is a unique multivalent carbohydrate binding molecule (mCBM) generated using Pneumagen’s proprietary GlycoTarge technology platform, that acts by binding to epithelial cell surface sialic acid receptors in the respiratory tract, thereby stopping viral entry at the site of infection by reducing their ability to enter host cells. Neumifil has shown potent antiviral activity against a broad range of infections caused by influenza viruses, respiratory syncytial virus (RSV), SARS-CoV-2 and rhinovirus in preclinical studies, and its differentiated mechanism of action means it is less susceptible to direct viral resistance. 

[email protected]    

Upcoming Events

Haemovigilance Past, Present and Future

Regency Suite, Brighton Hilton Metropole
6–8 July

BSMT - The Genomic and Microbiology Revolution: In Technology We Trust?

Royal Air Force Museum, Hendon, London
19 July 2022

Arab Lab Live 2022

Dubai International Convention & Exhibition Centre Dubai World Trade Centre - Trade Centre - Trade Centre 2 - Dubai - United Arab Emirates
24 - 26 October 2022

Lab Innovations 2022

Hall 2 NEC, Birmingham
2 & 3 November 2022

MEDICA 2022

Messe Düsseldorf D-40474 Düsseldorf, Stockumer Kirchstraße 61
14 - 17 November 2022

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Haemovigilance Past, Present and Future

Regency Suite, Brighton Hilton Metropole
6–8 July

BSMT - The Genomic and Microbiology Revolution: In Technology We Trust?

Royal Air Force Museum, Hendon, London
19 July 2022

Arab Lab Live 2022

Dubai International Convention & Exhibition Centre Dubai World Trade Centre - Trade Centre - Trade Centre 2 - Dubai - United Arab Emirates
24 - 26 October 2022

Lab Innovations 2022

Hall 2 NEC, Birmingham
2 & 3 November 2022

MEDICA 2022

Messe Düsseldorf D-40474 Düsseldorf, Stockumer Kirchstraße 61
14 - 17 November 2022

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2022 Step Communications Ltd. Registered in England. Registration Number 3893025